COVID-19

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents | Antiviral Efficacy of Oral Ensitrelvir versus Oral Ritonavir-boosted Nirmatrelvir in COVID-19 (PLATCOV): An Open-label, Phase 2, Randomised, Controlled, Adaptive Trial | Longitudinal Patient-reported Outcome Trajectories in Long COVID: Findings from the STOP-PASC Clinical Trial

Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis | Neonatal Outcomes Among Pregnant Women with COVID-19: A Systematic Scoping Review and Meta-analysis | Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season | Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort | FDA Conditionally Approves First Drug for Prevention and Treatment of New World Screwworm Infestations in Cattle September 30, 2025

Clesrovimab for Prevention of RSV Disease in Healthy Infants | Mexico Boosts Controls on Cattle after New Screwworm Case Found Near U.S. Border in Nuevo Leon | More Measles Cases Now in 2025 Than Any Year Since It Was Declared Eliminated in 2000

Tracking County-Level Measles Cases in the U.S. | Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza | Adverse Events Associated with COVID-19 Vaccination or Diagnosis among Pregnant and Non-pregnant Women in the United States, 2021-2022

Risk Factors for Severe Outcomes of Respiratory Syncytial Virus Infection in Children: A Nationwide Cohort Study in Sweden | Spillover of SARS-CoV-2 to Domestic Dogs in COVID-19–Positive Households: A One Health Surveillance Study

Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine A Prespecified Secondary Analysis of the Randomized DANFLU-2 Trial |

Three Pharmaceutical Companies Announce U.S. FDA Approval for Updated COVID. The U.S. FDA’s Center for Biologics Evaluation and Research has suspended the biologics license for Valneva Austria GmbH’s live – attenuated IXCHIQ vaccine.

Ivermectin to Control Malaria — A Cluster-Randomized Trial | Relative Effectiveness of High-dose versus Standard-dose Influenza Vaccine against Hospitalizations and Mortality According to Frailty Score: A Post-hoc Analysis of the DANFLU-1 Randomized Trial

Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated with Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years |